ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

Go back to ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
(NASDAQ: SPRY) Delayed: 5.62 -0.05 (0.88%)
Previous Close $5.67    52 Week High
Open $5.60    52 Week Low
Day High $5.70    P/E N/A 
Day Low $5.54    EPS
Volume 852,563